Maxime Dely: How Do We Balance Benefit and Risk in Chronic Hematologic Diseases?
Maxime Dely, Therapeutic Solutions Sales Consultant at Terumo Blood and Cell Technologies, shared a post on LinkedIn:
“Repeated transfusions: how do we balance benefit and risk in chronic hematologic diseases?
Every year, thousands of patients live thanks to repeated transfusions… but at what long-term cost?
In many chronic hematologic diseases (sickle cell disease, myelodysplastic syndromes, leukemias), red blood cell concentrates are essential to correct anemia
and maintain quality of life.
However, repeated transfusions carry well – documented risks: alloimmunization, making future transfusions more complex, and iron overload, which can lead to hepatic, cardiac, and endocrine complications that are often underestimated.
Iron chelation therapy then becomes necessary, yet burdensome.
Other challenges also arise, such as delayed hemolytic transfusion reactions, sometimes severe, and variability in transfusion thresholds, raising questions about optimal use.
Current guidelines emphasize a more restrictive and individualized approach, tailored to each patient’s condition and disease.
Transfusion is no longer just a supportive act – it is a true therapeutic lever, requiring careful balance between immediate clinical benefit and long-term impact.
Should we more broadly rethink transfusion strategies to better anticipate their chronic consequences?”

More posts featuring Maxime Dely on Hemostasis Today.
-
Nov 17, 2026, 15:26Hereditary Hemorrhagic Telangiectasia: The Molecular Connection Between Vascular Malformations and Bleeding
-
Nov 17, 2026, 14:54Cindy Neunert: Beyond Platelet Counts – Addressing Fatigue and Whole-Person Care in ITP
-
Nov 17, 2026, 14:44Strengthening Haemophilia Diagnosis Through Hands-On Laboratory Training – IAHAD
-
Nov 17, 2026, 14:40Platelet Membrane Protrusions Beyond Their Role in Hemostasis – JTH
-
Nov 17, 2026, 14:10Wolfgang Miesbach: Aspirin vs Anticoagulants – Who Needs More Than Aspirin?
-
Nov 17, 2026, 14:08Chaza Alaji: Soluble Transferrin Receptor – A Key to Uncovering Hidden Iron Deficiency
-
Nov 17, 2026, 14:03Shadi Tabibian: Fibrinogen – From Molecular Structure to Clinical Decision Making
-
Nov 17, 2026, 13:54Gabrielle Sarlon: Breaking the Silence on Menstrual Bleeding During Anticoagulant Therapy
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome